Abstract
Proteases have an important role in many signalling pathways, and represent potential drug targets for diseases ranging from cardiovascular disorders to cancer, as well as for combating many parasites and viruses. Although inhibitors of well-established protease targets such as angiotensin-converting enzyme and HIV protease have shown substantial therapeutic success, developing drugs for new protease targets has proved challenging in recent years. This in part could be due to issues such as the difficulty of achieving selectivity when targeting protease active sites. This Perspective discusses the general principles in protease-based drug discovery, highlighting the lessons learned and the emerging strategies, such as targeting allosteric sites, which could help harness the therapeutic potential of new protease targets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Turk, B. Targeting proteases: successes, failures and future prospects. Nature Rev. Drug Discov. 5, 785–799 (2006).
Smith, C. G. & Vane, J. R. The discovery of captopril. FASEB J. 17, 788–789 (2003).
Flexner, C., Bate, G. & Kirkpatrick, P. Tipranavir. Nature Rev. Drug Discov. 4, 955–956 (2005).
Melnikova, I. The anticoagulants market. Nature Rev. Drug Discov. 8, 353–354 (2009).
Rawlings, N. D., Morton, F. R., Kok, C. Y., Kong, J. & Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 36, D320–D325 (2008).
Timmer, J. C. et al. Structural and kinetic determinants of protease substrates. Nature Struct. Mol. Biol. 16, 1101–1108 (2009).
Davie, E. W. & Fujikawa, K. Basic mechanisms in blood coagulation. Annu. Rev. Biochem. 44, 799–829 (1975).
Davie, E. W. A brief historical review of the waterfall/cascade of blood coagulation. J. Biol. Chem. 278, 50819–50832 (2003).
Peden, J. C. Jr & Mc Farland, J. A. Use of the plasma thrombin time to assess the adequacy of in vivo neutralization of heparin: comparative studies following operations employing extracorporeal circulation. Blood 14, 1230–1236 (1959).
Bennett, B. & Ratnoff, O. D. The normal coagulation mechanism. Med. Clin. North Am. 56, 95–104 (1972).
Turk, B., Turk, D. & Salvesen, G. S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des 8, 1623–1637 (2002).
Van den Steen, P. E. et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375–536 (2002).
McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (2000).
Overall, C. M. & Dean, R. A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25, 69–75 (2006).
Sabeh, F., Shimizu-Hirota, R. & Weiss, S. J. Protease-dependent versus-independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 185, 11–19 (2009).
Cauwe, B., Van den Steen, P. E. & Opdenakker, G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42, 113–185 (2007).
Wolf, K., Muller, R., Borgmann, S., Brocker, E. B. & Friedl, P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 102, 3262–3269 (2003).
Uhlmann, F., Wernic, D., Poupart, M. A., Koonin, E. V. & Nasmyth, M. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. Cell 103, 375–386 (2000).
Kraft, C., Gmachl, M. & Peters, J. M. Methods to measure ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex. Methods 38, 39–51 (2006).
Reyes-Turcu, F. E., Ventii, K. H. & Wilkinson, K. D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363–397 (2009).
Krishnaswamy, S. Exosite-driven substrate specificity and function in coagulation. J. Thromb. Haemost. 3, 54–67 (2005).
Rijken, D. C. & Lijnen, H. R. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost. 7, 4–13 (2009).
Hu, J., Van den Steen, P. E., Sang, Q. X. & Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Rev. Drug Discov. 6, 480–498 (2007).
Dusing, R. & Sellers, F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr. Med. Res. Opin. 25, 2287–2301 (2009).
Maisey, H. C., Doran, K. S. & Nizet, V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev. Mol. Med. 10, e27 (2008).
Imamura, T., Potempa, J. & Travis, J. Activation of the kallikrein–kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases. Biol. Chem. 385, 989–996 (2004).
Adams, J. & Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304–311 (2004).
Green, D. R. & Evan, G. I. A matter of life and death. Cancer Cell 1, 19–30 (2002).
Mohamed, M. M. & Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer. Nature Rev. Cancer 6, 764–775 (2006).
Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25–35 (2004).
Troy, C. M. & Salvesen, G. S. Caspases on the brain. J. Neurosci. Res. 69, 145–150 (2002).
Lopez-Otin, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nature Rev. Cancer 7, 800–808 (2007).
Lu, X., Lu, D., Scully, M. & Kakkar, V. ADAM proteins — therapeutic potential in cancer. Curr. Cancer Drug Targets. 8, 720–732 (2008).
Palermo, C. & Joyce, J. A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 29, 22–28 (2008).
Mattos, C. et al. Multiple solvent crystal structures: probing binding sites, plasticity and hydration. J. Mol. Biol. 357, 1471–1482 (2006).
Kim, D. et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141–151 (2005).
Kim, D. et al. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing subsituted triazolopiperazines. J. Med. Chem. 51, 589–602 (2008).
Leiting, B. et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases, II, IV and VII. Biochem. J. 371, 525–532 (2003).
Rano, T. A. et al. A combinatorial approach for determining protease specificities: application to interleukin-1β converting enzyme (ICE). Chem. Biol. 4, 149–155 (1997).
Wood, W. J., Patterson, A. W., Tsuruoka, H., Jain, R. K. & Ellman, J. A. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 127, 15521–15527 (2005).
Thompson, L. A. & Ellman, J. A. Synthesis and applications of small molecule libraries. Chem. Rev. 96, 555–600 (1996).
Schneider, E. L. & Craik, C. S. Positional scanning synthetic combinatorial libraries for substrate profiling. Methods Mol. Biol. 539, 59–78 (2009).
Li, J. et al. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 280, 28766–28774 (2005).
Backes, B. J., Harris, J. L., Leonetti, F., Craik, C. S. & Ellman, J. A. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nature Biotechnol. 18, 187–193 (2000).
Harris, J. L. et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl Acad. Sci. USA 97, 7754–7759 (2000).
Drag, M. et al. Positional-scanning fluorigenic substrate libraries reveal unexpected specificity determinants of DUBs (deubiquitinating enzymes). Biochem. J. 415, 367–375 (2008).
Snipas, S. J., Drag, M., Stennicke, H. R. & Salvesen, G. S. Activation mechanism and substrate specificity of the Drosophila initiator caspase DRONC. Cell Death Differ. 15, 938–945 (2008).
Choe, Y. et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 281, 12824–12832 (2006).
Brak, K., Doyle, P. S., McKerrow, J. H. & Ellman, J. A. Identification of a new class of nonpeptidic inhibitors of cruzain. J. Am. Chem. Soc. 130, 6404–6410 (2008).
Inagaki, H. et al. Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode. J. Med. Chem. 50, 2693–2699 (2007).
Melnikova, I. Hepatitis C therapies. Nature Rev. Drug Discov. 7, 799–800 (2008).
Hu, J., Van den Steen, P. E., Dillen, C. & Opdenakker, G. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol. 70, 535–544 (2005).
Hu, J., Fiten, P., Van den Steen, P. E., Chaltin, P. & Opdenakker, G. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Anal. Chem. 77, 2116–2124 (2005).
Piccard, H. et al. “Reverse degradomics”, monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products. Electrophoresis 30, 2366–2377 (2009).
Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnol. 19, 661–667 (2001).
Turk, B. E. et al. MMP-20 is predominately a tooth-specific enzyme with a deep catalytic pocket that hydrolyzes type V collagen. Biochemistry 45, 3863–3874 (2006).
Turk, B. E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nature Struct. Mol. Biol. 11, 60–66 (2004).
Watzke, A. et al. Selective activity-based probes for cysteine cathepsins. Angew. Chem. Int. Edn Engl. 47, 406–409 (2008).
Matthews, D. J. & Wells, J. A. Substrate phage: selection of protease substrates by monovalent phage display. Science 260, 1113–1117 (1993).
Hansen, M. et al. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J. Biol. Chem. 280, 38424–38437 (2005).
Scholle, M. D. et al. Mapping protease substrates by using a biotinylated phage substrate library. Chembiochem 7, 834–838 (2006).
Timmer, J. C. & Salvesen, G. S. Caspase substrates. Cell Death Differ. 14, 66–72 (2007).
Impens, F. et al. MS-driven protease substrate degradomics. Proteomics 10, 1284–1296 (2010).
Chen, X. et al. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc. Natl Acad. Sci. USA 103, 14548–14553 (2006).
Pellecchia, M. et al. Perspectives on NMR in drug discovery: a technique comes of age. Nature Rev. Drug Discov. 7, 738–745 (2008).
Erlanson, D. A. et al. In situ assembly of enzyme inhibitors using extended tethering. Nature Biotechnol. 21, 308–314 (2003).
Eckelman, B. P., Salvesen, G. S. & Scott, F. L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7, 988–994 (2006).
Rydel, T. J. et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 249, 277–280 (1990).
Wada, C. K. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr. Top. Med. Chem. 4, 1255–1267 (2004).
Wang, J. et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 63, 7861–7869 (2003).
Forino, M. et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl Acad. Sci. USA 102, 9499–9504 (2005).
Hardy, J. A., Lam, J., Nguyen, J. T., O'Brien, T. & Wells, J. A. Discovery of an allosteric site in the caspases. Proc. Natl Acad. Sci. USA 101, 12461–12466 (2004).
Herman, G. A., Stein, P. P., Thornberry, N. A. & Wagner, J. A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther. 81, 761–767 (2007).
McKerrow, J. H., Engel, J. C. & Caffrey, C. R. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med. Chem. 7, 639–644 (1999).
Renatus, M. et al. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14, 1293–1302 (2006).
Mikolajczyk, J. et al. Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J. Biol. Chem. 282, 26217–26224 (2007).
Drag, M., Mikolajczyk, J., Krishnakumar, I. M., Huang, Z. & Salvesen, G. S. Activity profiling of human deSUMOylating enzymes (SENPs) with synthetic substrates suggests an unexpected specificity of two newly characterized members of the family. Biochem. J. 409, 461–469 (2008).
Reyes-Turcu, F. E. et al. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell 124, 1197–1208 (2006).
Kornacker, M. G. et al. An inhibitor binding pocket distinct from the catalytic active site on human β-APP cleaving enzyme. Biochemistry 44, 11567–11573 (2005).
Shahian, T. et al. Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat. Chem. Biol. 5, 640–646 (2009).
Schweizer, A. et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 15, 625–636 (2007).
Thornberry, N. A. et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272, 17907–17911 (1997).
Silverman, G. A. et al. The serpins are an expanding superfamily of structurally similar but funtionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293–33296 (2001).
Brennan, S. Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Eur. Respir. J. 29, 229–230 (2007).
Stoop, A. A. & Craik, C. S. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nature Biotechnol. 21, 1063–1068 (2003).
Dennis, M. S., Herzka, A. & Lazarus, R. A. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. J. Biol. Chem. 270, 25411–25417 (1995).
Levy, J. H. & O'Donnell, P. S. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin. Investig. Drugs 15, 1077–1090 (2006).
Xuan, J. A. et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 66, 3611–3619 (2006).
Sun, J., Pons, J. & Craik, C. S. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42, 892–900 (2003).
Devy, L. et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517–1526 (2009).
Lazarus, R. A., Olivero, A. G., Eigenbrot, C. & Kirchhofer, D. Inhibitors of tissue factor. Factor VIIa for anticoagulant therapy. Curr. Med. Chem. 11, 2275–2290 (2004).
Chang, M.W. et al. Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J. 429, 527–532 (2010).
Brenke, R. et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25, 621–627 (2009).
Bogoyevitch, M. A. & Fairlie, D. P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12, 622–633 (2007).
Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41–54 (2009).
Goodey, N. M. & Benkovic, S. J. Allosteric regulation and catalysis emerge via a common route. Nat. Chem. Biol. 4, 474–482 (2008).
Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B. C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nature Med. 8, 1175–1181 (2002).
Girolami, A., Randi, M. L., Gavasso, S., Lombardi, A. M. & Spiezia, F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis 17, 139–143 (2004).
Baglia, F. A. & Walsh, P. N. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J. Biol. Chem. 275, 20514–20519 (2000).
Renné, T. & Gailani, D. Role of factor XII in hemostasis and thrombosis: clinical implications. Expert Rev. Cardiovasc. Ther. 5, 733–741 (2007).
Duncan, R. C., Wijeyewickrema, L. C. & Pike, R. N. The initiating proteases of the complement system: controlling the cleavage. Biochimie 90, 387–395 (2008).
Fuentes-Prior, P. & Salvesen, G. S. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 384, 201–232 (2004).
Wilson, N. S., Dixit, V. & Ashkenazi, A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunol. 10, 348–355 (2009).
Riedl, S. J. & Salvesen, G. S. The apoptosome: signalling platform of cell death. Nature Rev. Mol. Cell Biol. 5, 405–413 (2007).
LeMosy, E. K., Tan, Y. Q. & Hashimoto, C. Activation of a protease cascade involved in patterning the Drosophila embryo. Proc. Natl Acad. Sci. USA 98, 5055–5060 (2001).
Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002).
Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941–946 (2006).
Jensen, C., Herold, P. & Brunner, H. R. Aliskiren: the first renin inhibitor for clinical treatment. Nature Rev. Drug Discov. 7, 399–410 (2008).
Szelke, M. et al. Potent new inhibitors of human renin. Nature 299, 555–557 (1982).
Clozel, J. P. & Fischli, W. Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung 43, 260–262 (1993).
Sureshkumar, K. K. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc. Health Risk Manag. 4, 1205–1220 (2008).
Thornberry, N. A. & Weber, A. E. Discovery of Januvia (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem. 7, 557–568 (2007).
Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 47, 4135–4141 (2004).
Liu, Y. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837–846 (2003).
Stack, C. M. et al. Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J. Biol. Chem. 282, 2069–2080 (2007).
Cunningham, E., Drag, M., Kafarski, P. & Bell, A. Chemical target validation studies of aminopeptidase in malaria parasites using α-aminoalkylphosphonate and phosphonopeptide inhibitors. Antimicrob. Agents Chemother. 52, 3221–3228 (2008).
Maric, S. et al. The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: the importance of active site metal ions in the binding of substrates and inhibitors. Biochemistry 48, 5435–5439 (2009).
Skinner-Adams, T. S. et al. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. J. Med. Chem. 50, 6024–6031 (2007).
Kuebler, P. S. Method of treating stroke with thrombolytic agent. US patent 20080107641 (2007).
Rojkjaer, R. G. ). Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides. US patent 20030118574 (2002).
Varadarajan, N., Georgiou, G. & Iverson, B. L. An engineered protease that cleaves specifically after sulfated tyrosine. Angew. Chem. Int. Ed Engl. 47, 7861–7863 (2008).
Varadarajan, N., Rodriguez, S., Hwang, B. Y., Georgiou, G. & Iverson, B. L. Highly active and selective endopeptidases with programmed substrate specificities. Nature Chem. Biol. 4, 290–294 (2008).
Madison, E. L., Thanos, C., Ruggles, S. W. & Coughlin, S. Modified factor VII polypeptides and uses thereof. US patent 20090098103 (2008).
Tanaka, F. Catalytic antibodies as designer proteases and esterases. Chem. Rev. 102, 4885–4906 (2002).
Reverter, D. & Lima, C. D. A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2–SUMO complex. Structure 12, 1519–1531 (2004).
Friedrich, R., Steinmetzer, T., Huber, R., Sturzebecher, J. & Bode, W. The methyl group of Nα(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage. J. Mol. Biol. 316, 869–874 (2002).
Lupardus, P. J., Shen, A., Bogyo, M. & Garcia, K. C. Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science 322, 265–268 (2008).
Schecter, I. & Berger, M. On the size of the active site in proteases. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
Matheson, A.J. & Goa, K.L. Desirudin: a review of its use in the management of thrombotic disorders. Drugs 60, 679–700 (2000).
Kakar, P., Watson, T. & Lip, G.Y. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. Curr. Opin. Investig. Drugs 8, 256–265 (2007).
Eriksson, B.I., Smith, H., Yasothan, U. & Kirkpatrick, P. Dabigatran etexilate. Nature Rev. Drug Discov. 7, 557–558 (2008).
Matsuo, T., Koide, M. & Kario, K. Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin. Thromb. Hemost. 23, 517–522 (1997).
Acknowledgements
The Salvesen laboratory is supported by National Institutes of Health grants CA69381, RR20843 and NS61758, and by the Human Frontier Science Program grant RGP0024. The Drag laboratory is supported by the Foundation for Polish Science and the State for Scientific Research Grant N N401 042838 in Poland. The authors would like to thank E. Madison, B. Turk and the members of their laboratories for helpful discussions.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- Active site
-
Region in the enzyme in which the primary substrate binding site is localized and catalysis occurs. Usually the active site is on the surface of the enzyme and is made up of pockets defined by protein surfaces, which are responsible for the specific binding of the substrate amino acid residues next to the scissile bond.
- Allosteric site
-
Region of the enzyme that does not participate directly in substrate recognition and processing. Through the ability to interact with specific modulators (proteins or small molecules) the allosteric site enhances or inhibits substrate to product transition through conformational changes in the enzyme.
- Exosite
-
Region of the enzyme distant from the active site that is responsible for specific substrate–enzyme interactions. Exosite interactions influence the rates of catalysis, and sometimes of substrate specificity, of a given protease. Classic examples are the recognition of fibrinogen by thrombin, ubiquitin recognition by ubiquitin-specific peptidases (deubiquitylating enzymes or DUBs), and small ubiquitin-like modifier (SUMO) recognition by SUMO-specific proteases (SENPs).
Rights and permissions
About this article
Cite this article
Drag, M., Salvesen, G. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9, 690–701 (2010). https://doi.org/10.1038/nrd3053
Issue Date:
DOI: https://doi.org/10.1038/nrd3053
This article is cited by
-
Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies
Journal of Nanobiotechnology (2023)
-
TMPRSS4, a type II transmembrane serine protease, as a potential therapeutic target in cancer
Experimental & Molecular Medicine (2023)
-
Deubiquitinase YOD1 suppresses tumor progression by stabilizing E3 ligase TRIM33 in head and neck squamous cell carcinoma
Cell Death & Disease (2023)
-
Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration
Nature Communications (2022)
-
Keratinolytic protease from Pseudomonas aeruginosa for leather skin processing
Journal of Genetic Engineering and Biotechnology (2021)